Investors bought shares of Celgene Corporation (NASDAQ:CELG) on weakness during trading hours on Friday. $161.76 million flowed into the stock on the tick-up and $111.70 million flowed out of the stock on the tick-down, for a money net flow of $50.06 million into the stock. Of all equities tracked, Celgene Corporation had the 12th highest net in-flow for the day. Celgene Corporation traded down ($0.12) for the day and closed at $102.34

Several research analysts have recently commented on CELG shares. Zacks Investment Research raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and set a $151.00 target price on the stock in a report on Tuesday, July 18th. Robert W. Baird reaffirmed an “outperform” rating and set a $162.00 target price on shares of Celgene Corporation in a report on Friday, July 21st. Mizuho set a $134.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Wednesday, July 26th. Cantor Fitzgerald set a $160.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Thursday, July 27th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $150.00 target price on shares of Celgene Corporation in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $139.64.

The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65. The stock has a market cap of $80,574.02, a P/E ratio of 15.99, a price-to-earnings-growth ratio of 0.79 and a beta of 1.79.

Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same period in the previous year, the firm posted $1.58 earnings per share. The business’s revenue was up 10.2% compared to the same quarter last year. research analysts predict that Celgene Corporation will post 6.67 EPS for the current fiscal year.

In other Celgene Corporation news, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 20,227 shares of company stock valued at $2,843,956. Insiders own 0.95% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Capital Counsel LLC NY increased its stake in Celgene Corporation by 0.4% in the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC increased its position in shares of Celgene Corporation by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 11 shares in the last quarter. Sowell Financial Services LLC increased its position in shares of Celgene Corporation by 0.5% during the first quarter. Sowell Financial Services LLC now owns 2,454 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 13 shares in the last quarter. South Texas Money Management Ltd. increased its position in shares of Celgene Corporation by 0.6% during the first quarter. South Texas Money Management Ltd. now owns 2,453 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 15 shares in the last quarter. Finally, Flagship Harbor Advisors LLC increased its position in shares of Celgene Corporation by 0.9% during the first quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock worth $253,000 after acquiring an additional 18 shares in the last quarter. 78.92% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Investors Buy Celgene Corporation (CELG) on Weakness” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/11/12/investors-buy-celgene-corporation-celg-on-weakness.html.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.